Drugs / Venlafaxine XR
Venlafaxine XR
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00151450 | Mar 2005 → Nov 2006 | anxiety | Viatris Inc. | Completed | No outcome recorded |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT02977299 | Jul 2017 → Apr 2022 | major depressive disorder | Massachusetts General Hospital | Completed | Met primary |
| Phase 4 | NCT01916824 | Aug 2013 → Dec 2015 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT06965569 Background | Apr → Dec 2025 | — | Alar Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03538691 Background | Jul 2018 → Jul 2022 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | Missed primary |
| Phase 4 | NCT00693849 Comparator | Sep 2008 → Dec 2019 | major depressive disorder | BRC Operations Pty. Ltd. | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-04-19 | Wockhardt | WOCKHARDT RECEIVES US FDA APPROVAL FOR GENERIC VERSION OF EFFEXOR XR® CAPSULES wockhardt.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | venlafaxine-XR | “The objective of this study was to evaluate the anxiolytic efficacy, and speed of onset of efficacy, of pregabalin (PGB) and venlafaxine-XR (VXR) in patients with generalized...” PMID 21456104 ↗ Mar 20096“venlafaxine XR (Effexor XR®) extended-release (XR) capsules” NCT03538691 ↗ “Venlafaxine XR, Effexor XR” NCT01916824 ↗ |
| Known as | Effexor XR | “venlafaxine XR (Effexor XR®) extended-release (XR) capsules” NCT03538691 ↗ |
| Known as | Venlafaxine XR, Effexor XR | “Venlafaxine XR, Effexor XR” NCT01916824 ↗ |
| Known as | VXR | “The objective of this study was to evaluate the anxiolytic efficacy, and speed of onset of efficacy, of pregabalin (PGB) and venlafaxine-XR (VXR) in patients with generalized...” PMID 21456104 ↗ Mar 2009 |
| Route | Oral | “Oral switch therapy with venlafaxine, dose adjusted for effectiveness and tolerability.” NCT02977299 ↗ |